Two Layers of Gene Regulation Converge This study reveals an unexpected connection between two distinct layers of gene regulation: microRNA-mediated post-transcriptional regulation and N6-methyladenosine (m6A) RNA methylation. The finding that a tumor suppressor miRNA controls global m6A levels by targeting a key m6A reader protein opens a new dimension in understanding how liver cancer cells dysregulate gene expression.
miR-145 as a Tumor Suppressor miR-145 is one of the most consistently reported tumor suppressor miRNAs in human cancers. In hepatocellular carcinoma (HCC), miR-145 expression is reduced compared to normal liver tissue, and restoring miR-145 expression in HCC cell lines inhibits their growth. The downstream targets through which miR-145 suppresses HCC were not fully understood.
The m6A Modification and YTHDF2 N6-methyladenosine (m6A) is the most abundant internal modification in mammalian mRNA. The YTHDF family of proteins are m6A 'reader' proteins that recognize and respond to this modification: YTHDF2 specifically promotes the degradation of m6A-marked mRNAs, while YTHDF1 promotes their translation. Altered m6A levels are increasingly recognized as important in cancer biology.
The miR-145-YTHDF2 Axis The core finding is that miR-145 directly targets the 3'-UTR of YTHDF2 mRNA, reducing YTHDF2 protein levels. Since YTHDF2 promotes mRNA degradation, reducing YTHDF2 leads to stabilization of m6A-marked mRNAs and an overall increase in cellular m6A content. This cascade connects miR-145 loss (common in HCC) to elevated YTHDF2 and dysregulated m6A metabolism.
Inverse Correlation in HCC Tissue Analysis of HCC tissue samples from patients showed a significant negative correlation between miR-145 expression and YTHDF2 protein levels. In tumors where miR-145 was low, YTHDF2 protein was high, and vice versa. This inverse relationship in human tissue is consistent with miR-145 being a direct upstream regulator of YTHDF2.
YTHDF2 Overexpression in High-Grade HCC YTHDF2 was found to be overexpressed in 83.9% of grade III (poorly differentiated) HCC specimens, but at lower rates in grade I and II tumors. This grade-specific elevation suggests that YTHDF2 upregulation contributes to the more aggressive behavior of poorly differentiated HCC and may be a marker of tumor aggressiveness.
Clinical Significance of miR-145 Patients with lower miR-145 expression in their HCC tissues had significantly worse overall survival compared to patients with higher miR-145 levels. This prognostic association is consistent with miR-145 functioning as a biologically important tumor suppressor in HCC, and it supports considering miR-145 as a potential prognostic biomarker.
Correlation with m6A Levels Global m6A quantification in HCC tissues showed that tumors with low miR-145 and high YTHDF2 had reduced overall m6A content, consistent with YTHDF2-mediated accelerated degradation of m6A-marked transcripts. This change in total m6A content provides a biochemical readout linking the miR-145-YTHDF2 axis to the RNA methylation landscape of HCC.
Computational Prediction Bioinformatic analysis using miRNA target prediction algorithms (TargetScan, miRanda, PicTar) identified multiple potential binding sites for miR-145 in the 3'-UTR of YTHDF2 mRNA. The predicted binding site involves Watson-Crick base-pairing between the seed region of miR-145 and a complementary sequence in the YTHDF2 3'-UTR.
Luciferase Reporter Validation The miR-145-YTHDF2 interaction was confirmed using a dual-luciferase reporter assay: a luciferase reporter fused to the YTHDF2 3'-UTR was significantly repressed when miR-145 was co-transfected. Mutation of the predicted binding site abolished this repression, confirming that the effect is specifically mediated by the predicted seed match.
Endogenous Target Regulation Transfection of miR-145 mimics into HCC cells (HepG2 line) reduced endogenous YTHDF2 mRNA and protein levels in a dose-dependent manner. Conversely, transfection of miR-145 inhibitor (antisense oligonucleotide) increased YTHDF2 expression, confirming bidirectional regulation of the endogenous target.
Effect on m6A Levels After establishing direct targeting, the study confirmed that miR-145 transfection into HepG2 cells increased global m6A content, measured by dot blot with m6A antibody and LC-MS/MS quantification. This effect was dependent on YTHDF2 downregulation, as overexpressing YTHDF2 alongside miR-145 rescued the m6A increase, confirming YTHDF2 as the mediator.
miR-145 Suppresses HCC Cell Proliferation via YTHDF2 Overexpression of miR-145 in HepG2 HCC cells significantly reduced cell proliferation, as measured by MTT assay and BrdU incorporation. This growth-suppressive effect was partially reversed when YTHDF2 was co-overexpressed, demonstrating that YTHDF2 downregulation is a key mechanism through which miR-145 inhibits HCC cell growth.
Colony Formation Assay Soft agar colony formation assays showed that miR-145 transfection reduced anchorage-independent growth - a hallmark of malignant transformation. This effect was again rescued by YTHDF2 overexpression, confirming the functional importance of the miR-145-YTHDF2 axis in controlling tumorigenic properties.
Cell Cycle Effects Flow cytometric analysis showed that miR-145 transfection caused G1-phase cell cycle arrest in HCC cells, reducing the proportion of cells in S phase. Downstream cell cycle regulators including cyclin D1 and CDK4 were reduced, while p21 (a CDK inhibitor) was elevated. Some of these effects are likely mediated by YTHDF2 regulation, while others may reflect additional miR-145 targets.
Downstream m6A Targets The increase in m6A content following miR-145 transfection and YTHDF2 reduction stabilizes specific m6A-marked transcripts, some of which may encode tumor suppressor proteins that are normally rapidly degraded in HCC cells through YTHDF2-dependent decay. Identifying these stabilized transcripts is an important next step to fully explain how this axis suppresses tumor growth.
The m6A Writers and Erasers m6A is deposited on mRNA by the METTL3/METTL14/WTAP methyltransferase complex ('writers') and removed by ALKBH5 and FTO demethylases ('erasers'). Both writers and erasers show dysregulated expression in various cancers, and their specific functions are context-dependent - suggesting that the net effect of m6A in cancer depends on which specific mRNAs are methylated and which reader proteins are expressed.
YTHDF2 as an Oncogene This study's finding that YTHDF2 is overexpressed in high-grade HCC is consistent with emerging evidence that YTHDF2 can function as an oncogene by accelerating degradation of m6A-modified tumor suppressor mRNAs. The specific tumor suppressor transcripts that YTHDF2 degrades in HCC are an important area for further investigation.
miRNA-Epitranscriptome Crosstalk The miR-145-YTHDF2 link represents a previously unappreciated layer of crosstalk between the miRNA regulatory system and the RNA epitranscriptome (m6A). This interaction means that changes in miRNA expression (which are widespread in cancer) can have downstream effects on the global m6A landscape, potentially amplifying their effect on gene expression.
Therapeutic Targeting Potential The YTHDF2-m6A axis could be targeted therapeutically in HCC. Restoring miR-145 expression using miRNA replacement therapy, or directly inhibiting YTHDF2, could restore normal m6A patterns and suppress tumor growth. Several YTHDF2-targeting approaches are feasible including siRNA, antisense oligonucleotides, or small-molecule inhibitors.
Identifying m6A-Marked Tumor Suppressor Targets A key unanswered question is which specific mRNAs are stabilized when YTHDF2 is reduced, and which of these explain the growth-suppressive effects. m6A-seq (transcriptome-wide m6A profiling) combined with RNA-seq in miR-145/YTHDF2 manipulation experiments would identify the relevant downstream transcripts.
In Vivo Validation The study demonstrated in vitro effects in HCC cell lines. Validation in animal models - testing whether miR-145 restoration or YTHDF2 inhibition suppresses HCC tumor growth in vivo - is needed before considering clinical translation. Xenograft experiments with HCC cells manipulated for this axis would provide the necessary in vivo evidence.
Other miRNAs Targeting m6A Regulators This study focused on miR-145 and YTHDF2, but other miRNAs might regulate YTHDF1, YTHDC1, METTL3, METTL14, or ALKBH5. Systematic analysis of miRNA targeting of all m6A pathway components could reveal a broader regulatory network connecting miRNA dysregulation to the cancer epitranscriptome.
Clinical Utility Can the miR-145 - YTHDF2 inverse relationship be exploited as a composite biomarker for HCC prognosis? Measuring both miR-145 and YTHDF2 together might outperform either marker alone. Prospective validation in larger patient cohorts with clinical outcome data would be needed to establish this potential clinical utility.